Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s Disease (LGD) in the US, is a progressive neurodegenerative disease. Although relatively rare, with 2 new… More >>

Dear ALS/MND Community, We are writing to inform you that Ionis has completed enrollment of FUSION (NCT04768972), the pivotal Phase 3 clinical trial of our investigational medicine, ulefnersen (ION363). FUSION… More >>

• DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo • DAZALS met… More >>

Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves… More >>

Dear ALS community, We are pleased to share that Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and… More >>

TRICALS, in collaboration with King’s College London and Macquarie University, announced that the global Phase 3 placebo-controlled Lighthouse II study was terminated after the interim analysis did not demonstrate an… More >>

Reldesemtiv in Amyotrophic Lateral Sclerosis Results From the COURAGE-ALS Randomized Clinical Trial Key Points Question Does orally administered reldesemtiv slow disease progression in amyotrophic lateral sclerosis (ALS)? Findings A Study to Evaluate… More >>

Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter… More >>